The Webinar Series will take place bi-weekly on: Thursdays

12 pm noon (EST)

9 am (PST), 5 pm (GMT), 6 pm (CET)

We will use a single Zoom webinar registration for the upcoming seminars:

https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

Some seminars might be recorded and accessible for a limited time.

 

Upcoming Speakers

James (Jay) Bradner

Novartis

 

February 4th, 2021 

Molecular Glues

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Radek Nowak

 

James (Jay) Bradner, M.D., joined Novartis on January 1, 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) on March 1, 2016. He is a member of the Executive Committee of Novartis.
Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. Dr. Bradner is a co-founder of five biotechnology companies and has authored more than 250 scientific publications and 50 US patent applications.
Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women's Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Sagar Koduri and Matthew Oser

Dana-Farber Cancer Institute

February 18th, 2021 

Targeting Oncoproteins With A Positive Selection Assay For Protein Degraders

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

Host: Xiaoxi Liu

Sagar Koduri is an oncologist at the Dana Farber Cancer Institute, with a specialized interest in hematologic malignancies, and a postdoctoral fellow in the laboratory of Dr. William G. Kaelin, Jr. In conjuction with the Oser Lab, Sagar will present work on use of zinc finger degrons as tools to modulate protein expression, and the development of a positive-selection assay to identify protein degraders of undruggable proteins.

 

Matthew Oser is an thoracic oncologist and head of the Oser laboratory at Dana Farber Cancer Institute. He completed his postdoctoral fellowship in Dr. William G. Kaelin Jr's laboratory and, in 2019, started his own laboratory focused identifying new therapeutic targets in small cell lung cancer. In collaboration with Drs. Kaelin and Koduri, his lab has used CRISPR/Cas9 positive selection screening to identify protein degraders of neuroendocrine transcription factors in small cell lung cancer.

 

March 4th, 2021 

Unlocking the dynamic cellular mechanisms of targeted protein degradation

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Breanna Zerfas

 
 
 
 
 

Danette Daniels

Promega Corporation

Danette received her B.A. from Columbia University, a Ph.D. in Biophysics from Yale University, and completed a postdoctoral fellowship at Stanford University School of Medicine studying the Wnt signaling pathway.  In 2005 she joined Promega Corporation and is currently a R&D Group Leader of Functional Proteomics.  In her time at Promega she has led innovation and applications of HaloTag, chemoproteomics, NanoBRET, and HiBiT luciferase technologies.  Danette is known for her extensive research collaborations, both with academic laboratories as well as biotech and pharma companies.  These partnerships have resulted in discoveries of several novel epigenetic and transcription complexes, as well as characterization of numerous therapeutic inhibitors. Several years ago she and her team shifted focus to TPD, immediately developing approaches to monitor real-time kinetics of degradation and PROTAC induced interactions.  These efforts have advanced understanding of cellular potency, efficacy, and mechanisms of degradation compounds.

David Komander

Walter and Eliza Hall Institute of Medical Research

March 18th, 2021 

Deubiquitinases: Opportunities, observations and open questions

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Katherine Donovan

 

David Komander studied in Germany and Scotland, working on protein kinase structures during his PhD in Dundee. As a postdoc in London, he initiated work on tumour suppressor deubiquitinases, leading to the first structures on CYLD and A20. Focussing on E3 ligases, ubiquitin binding domains and deubiquitinases, he went on to set up his own highly successful research group at the MRC Laboratory of Molecular Biology in Cambridge, UK.  He was recipient for the Lister prize in 2012 and became an EMBO member in 2014.

At the end of 2018 David Komander moved to Australia to become head of the newly founded Ubiquitin Signalling Division at the Water and Eliza Hall Institute in Parkville, Australia.

April 1st, 2021 

TBA

Webinar registration: https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ

 

Host: Breanna Zerfas

 
 
 
 
 

Matthew Disney